New business models for antibiotic innovation

References

• Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;16:184–94.
   Google Scholar
• Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—time to react is now. Drug Resist Updat. 2011;14:118–24.
   PubMed Web of Science ®Google Scholar
• Hamad B. The antibiotics market. Nat Rev Drug Discov. 2010;9:675–6.
   PubMed Web of Science ®Google Scholar
• Stewart JJ, Allison PN, Johnson RS. Putting a price on biotechnology. Nat Biotechnol. 2001;19:813–17.
   Google Scholar
• Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6:427–30.
   PubMed Web of Science ®Google Scholar
• Powers JH. Antimicrobial drug development—the past, the present, and the future. Clin Microbiol Infect. 2004;10:23–31.
   PubMed Web of Science ®Google Scholar
• Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1–120.
   PubMedGoogle Scholar
• So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011;14:88–94.
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2006;6:29–40.
   PubMed Web of Science ®Google Scholar
• O’Shea R, Mosser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem. 2008;51:2871–8.
   PubMed Web of Science ®Google Scholar
• Fernandes P. Antibacterial discovery and development—the failure of success? Nat Biotechnol. 2006;24:1497–503.
   PubMed Web of Science ®Google Scholar
• DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther. 1995;58:1–14.
   PubMed Web of Science ®Google Scholar
• Evans R, Hinds S, Hammock D. Portfolio analysis and R&D decision making. Nat Rev Drug Discov. 2009;8:189–90.
   PubMed Web of Science ®Google Scholar
• US FDA Center for Drug Evaluation and Research. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2010.
   Google Scholar
• Outterson K, Powers JH, Seoane-Vasquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980–2009. J Law Med Ethics. 2013;41:688–96.
   Web of Science ®Google Scholar
• Ross D. The FDA and the case of Ketek. N Engl J Med. 2007;356:1601–4.
   PubMed Web of Science ®Google Scholar
• Soreth J, Cox E, Kweder S, Jenkins J, Galson S. Ketek—the FDA perspective. N Engl J Med. 2007;356:1675–6.
   PubMed Web of Science ®Google Scholar
• Carome M, Wolfe SM. Public citizen letter to FDA opposing approval of bedaquiline, December 21. 2012. Available at http://www.citizen.org/documents/2088.pdf. Accessed on: December 13, 2013
   Google Scholar
• Love J, Hubbard T. The big idea: prizes to stimulate R&D for new medicines. Chic Kent Law Rev. 2007;82:1519–50.
   Google Scholar
• So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ. Antibiotic resistance - the need for global solutions. Part 5: the access and excess dilemma (pp. 1071–5). Lancet Infect Dis. 2013;13:1057–98.
   Google Scholar
• Critical Path Institute [Internet]. Coalition Against Major Diseases [Internet]. 2013. Available at http://c-path.org/programs/camd/camd-overview/camd-progress/. Accessed on: December 14, 2013.
   Google Scholar
• So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ. 2012;344:e1782.
   PubMedGoogle Scholar
• Pelaez F. The historical delivery of antibiotics from microbial natural products—can history repeat? Biochem Pharmacol. 2006;71:981–90.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.
   PubMed Web of Science ®Google Scholar
• Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE, et al. Responding to market failures in tuberculosis control. Science. 2001;293:1049–51.
   PubMed Web of Science ®Google Scholar